Overview

A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma

Status:
Completed
Trial end date:
2015-02-13
Target enrollment:
Participant gender:
Summary
This is a non-randomized open label multicentre Phase II trial to evaluate the response rate of PF03446962 in patients with advanced malignant pleural mesothelioma who have been previously treated with cytotoxic chemotherapy.
Phase:
Phase 2
Details
Lead Sponsor:
NCIC Clinical Trials Group
Collaborator:
Pfizer
Treatments:
Antibodies, Monoclonal